Effect of Sophora flavescens on the pharmacokinetics of carbamazepine in rats

被引:11
|
作者
Shi, Lei [1 ]
Dang, Xue-Liang [1 ]
Liu, Xin-You [1 ]
Wei, Hua-Mei [1 ]
Yang, Meng-Meng [1 ]
Zhang, Yan [1 ]
机构
[1] Fourth Mil Med Univ, Tangdu Hosp, Dept Pharm, Xian 710038, Peoples R China
关键词
Sophora flavescens; Carbamazepine; Carbamazepine-10,11-epoxide; Pharmacokinetics; Herb-drug interaction; HEPATIC-FIBROSIS; IN-VITRO; OXYMATRINE; ZONISAMIDE; METABOLISM; MATRINE; MICE;
D O I
10.1007/s12272-014-0375-8
中图分类号
R914 [药物化学];
学科分类号
100701 ;
摘要
Carbamazepine (CBZ), an antiepileptic with narrow therapeutic window, is a substrate of CYP 3A4 which metabolizes CBZ to carbamazepine-10,11-epoxide (CBZE). CBZE is an active and toxicity metabolite, and it is a substrate of MRP-2. Using CBZ for a long time can cause hepatic injury. Sophora flavescens (SF) is a medicinal herb used for the protected hepatic injury. This study investigated the acute and chronic effects of SF on the pharmacokinetics of CBZ in rats. The concentrations of CBZ and CBZE in plasma and tissues were determined by HPLC method. The results showed that SF which significantly decreased the AUC(0-t) of CBZ, increased CBZE conversely. Tissue analysis showed that the concentrations of CBZ and CBZE in brain and liver were decreased by SF. In addition, the distribution of CBZE in kidney was reduced significantly, which influenced the CBZE excretion and increased the drug toxic potentially. Results in the current study suggest that patients using CBZ might be cautioned in the use of SF extract or Sophora-derived products. Meanwhile, patients receiving drugs which are substrates of CYP 3A4 and/or MRP-2 should be advised of the potential herb-drug interaction to reduce the risk of therapeutic failure or increased toxicity of conventional drug therapy.
引用
收藏
页码:1617 / 1623
页数:7
相关论文
共 50 条
  • [1] Effect of Sophora flavescens on the pharmacokinetics of carbamazepine in rats
    Lei Shi
    Xue-Liang Dang
    Xin-You Liu
    Hua-Mei Wei
    Meng-Meng Yang
    Yan Zhang
    Archives of Pharmacal Research, 2014, 37 : 1617 - 1623
  • [2] Study on pharmacokinetics of sophora flavescens injection in rabbits
    Natl. Inst. Contr. Pharmaceut. Prod., Beijing 100050, China
    Chinese Pharmaceutical Journal, 2002, 37 (07) : 524 - 526
  • [3] Sex Difference of Effect of Sophora flavescens on Gut Microbiota in Rats
    Duan, Xueqing
    Xie, Xin
    Zhu, Chen
    Duan, Zhixuan
    Chen, Rui
    Xu, Jun
    Zhang, Qi
    Yu, Qi
    Tian, Weiyi
    EVIDENCE-BASED COMPLEMENTARY AND ALTERNATIVE MEDICINE, 2022, 2022
  • [4] Hepatotoxicity Induced by Sophora flavescens and Hepatic Accumulation of Kurarinone, a Major Hepatotoxic Constituent of Sophora flavescens in Rats
    Jiang, Peng
    Zhang, Xiuwen
    Huang, Yutong
    Cheng, Nengneng
    Ma, Yueming
    MOLECULES, 2017, 22 (11):
  • [5] The effect of cannabidiol on the pharmacokinetics of carbamazepine in rats
    Ruba S. Darweesh
    Tareq N. Khamis
    Tamam El-Elimat
    Naunyn-Schmiedeberg's Archives of Pharmacology, 2020, 393 : 1871 - 1886
  • [6] The effect of cannabidiol on the pharmacokinetics of carbamazepine in rats
    Darweesh, Ruba S.
    Khamis, Tareq N.
    El-Elimat, Tamam
    NAUNYN-SCHMIEDEBERGS ARCHIVES OF PHARMACOLOGY, 2020, 393 (10) : 1871 - 1886
  • [7] Whitening effect of Sophora flavescens extract
    Shin, Dae Hyun
    Cha, Youn Jeong
    Joe, Gi Jung
    Yang, Kyeong Eun
    Jang, Ik-Soon
    Kim, Bo Hyeon
    Kim, Jung Min
    PHARMACEUTICAL BIOLOGY, 2013, 51 (11) : 1467 - 1476
  • [8] Sedative Effect of Sophora flavescens and Matrine
    Lee, Hyun-ju
    Lee, Sun-young
    Jang, Daehyuk
    Chung, Sun-Yong
    Shim, Insop
    BIOMOLECULES & THERAPEUTICS, 2017, 25 (04) : 390 - 395
  • [9] THE ANTIARRHYTHMIC EFFECTS OF SOPHORA FLAVESCENS AIT IN RATS AND MICE
    DAI, S
    CHAN, MY
    LEE, SS
    OGLE, CW
    AMERICAN JOURNAL OF CHINESE MEDICINE, 1986, 14 (3-4): : 119 - 123
  • [10] Effect of soybean administration on the pharmacokinetics of carbamazepine and omeprazole in rats
    Singh, Dharmender
    Asad, Mohammed
    FUNDAMENTAL & CLINICAL PHARMACOLOGY, 2010, 24 (03) : 351 - 355